
Ardian-backed Ionisos buys Scandinavian Clinics Estonia
Ionisos, backed by buyout house Ardian, has acquired a majority stake in Baltic gamma ray sterilisation specialist Scandinavian Clinics Estonia.
Ardian's expansion team led the transaction, which is the fourth external growth operation carried out by Ionisos since the GP acquired a majority stake in July 2016.
The deal was self-financed and no additional equity was used, the company confirmed with unquote".
With the new acquisition, the company intends to develop through organic growth and further acquisitions.
Ardian acquired its stake in Ionisos via its Expansion Fund IV, which held a €1bn final close in June 2016.
Ardian was initially attracted to the company by its potential to expand geographically to the north and east of Europe, serving Finland, Sweden, Norway and the Baltic countries, a company spokesperson told unquote".
Company
Founded in 2007 and based in Harju County in Estonia, near Tallinn, Scandinavian Clinics Estonia provides gamma-ray sterilisation treatment in the Baltic states. The company states it has the capacity to also meet the sterilisation needs of northern Europe, specifically in Norway, Sweden, Finland and Poland.
Following the acquisition, the group will be renamed Ionisos Baltics.
People
Ardian – François Jerphagnon (head of expansion team).
Ionisos – Christoph Herkens (managing director).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater